SCLC is characterized by loss of RB1 (George et al, 2015), the predominant regulator of G1/S transition leading to increased reliance on cyclin‐dependent kinase inhibitor p21 (CDKN1A) for control of the G1/S checkpoint (Hauge et al, 2019). Here, RB1 is linked to small cell lung carcinoma.